The ASPE issue brief examines the research and development cost and duration associated with bringing novel vaccines to the U.S. market. The results indicate that bringing a novel vaccine to the U.S. market costs an estimated $886.8 million on average, and its development process lasts 10 years.
Health & Health Care
ASPE produces health policy research with a focus on equity, coverage, and access. Find resources related to a broad range of topics, including the uninsured population, vaccine hesitancy, Medicaid/CHIP, Medicare, the federal marketplace (HealthCare.gov), telehealth, health care delivery, underserved areas, delivery system transformation, health outcomes, and social determinants of health.
Noteworthy Resources and Reports
Vaccine Hesitancy for COVID-19: State, County, and Local Estimates
To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates using the most recently available federal survey data. Explore the interactive map and other resources.
Topic Areas
Reports
Displaying 31 - 40 of 1576. 10 per page. Page 4.
Advanced SearchASPE Issue Brief, Report
New Estimates of the Cost of Preventive Vaccine Development and Potential Implications from the COVID-19 Pandemic
ASPE Issue Brief
Health Insurance Coverage and Healthcare Access from 2021-2024
This Issue Brief investigates how health insurance coverage, as well as healthcare access and affordability, has changed in recent years, with an emphasis on policies implemented from 2021 to 2024. Over 300 million Americans now have health insurance coverage. The U.S. uninsured rate has fallen significantly over the past four years.
ASPE Issue Brief
Behavioral Health Service Use Among Medicaid and CHIP Enrollees Before/During the COVID-19 Public Health Emergency
In 2020, 53 million adults in the United States had a mental health condition and 40 million people ages 12 and older had a substance use disorder (SUD). The COVID-19 public health emergency (PHE) exacerbated mental health conditions and SUDs at a time when access to in-person care was restricted due to safety concerns.
Report
Assessing the Feasibility of Creating a National Behavioral Health Workforce Database
The U.S. behavioral health (BH) workforce faces significant shortages and distribution disparities, hindering access to quality care and worsening health outcomes. A comprehensive, centralized database of BH providers is vital for advancing patient-centered outcomes research (PCOR), comparative effectiveness research (CER), and evidence-based policymaking.
ASPE Issue Brief
Operationalizing the Definition of Intellectual and Developmental Disabilities in Administrative Claims Data for Research
The existence of multiple operational definitions for intellectual and developmental disabilities (ID/DD) in analyzing administrative claims data for health services and public health research limits translation of study findings to inform policies, programs, and practice.
Report
The Implications of the No Surprises Act on Contract Dynamics, Negotiations, and Finances
To explore whether and how the NSA has affected insurer-provider dynamics, contract negotiations, and payment rates, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) asked RAND to conduct discussions with stakeholders. In this report, RAND summarizes the approach exploring these topics, the themes that emerged from our discussions, and areas for additional inquiry.
ASPE Issue Brief
Treatment for Children and Adolescents Enrolled in Medicaid and CHIP During COVID-19
The first brief below provides insight into children’s and adolescents’ mental health service use in Medicaid and CHIP during the pandemic, by using a national Medicaid claims database.
ASPE Issue Brief
Medicaid Behavioral Health Providers Delivering Most Behavioral Health Services via Telehealth Before and During the COVID-19 Pandemic Issue Brief
The goal of this study was to examine the extent to which Medicaid providers who deliver behavioral health services shifted their practices to mostly tele-behavioral health services during the COVID-19 pandemic.
ASPE Issue Brief, Report
An Evaluation Framework for the Inflation Reduction Act’s Medicare Prescription Drug Related Provisions
The Inflation Reduction Act (IRA) changes the way Medicare pays for prescription drugs. These changes will impact various stakeholders, including Medicare, Medicare enrollees, drug manufacturers, and others.
ASPE Issue Brief
An Examination of the Return on Investment of Generic Injectable Prescription Drugs
The generic injectable drug market has recently experienced numerous shortages, which impose substantial public health costs. One potential cause of these shortages is low profitability of generic injectables. This brief examines the profitability of recently launched generic injectables.